全文获取类型
收费全文 | 844425篇 |
免费 | 91533篇 |
国内免费 | 544篇 |
出版年
2018年 | 8575篇 |
2017年 | 7997篇 |
2016年 | 11732篇 |
2015年 | 16380篇 |
2014年 | 19109篇 |
2013年 | 26362篇 |
2012年 | 30012篇 |
2011年 | 30258篇 |
2010年 | 20403篇 |
2009年 | 18588篇 |
2008年 | 26475篇 |
2007年 | 26932篇 |
2006年 | 25218篇 |
2005年 | 24226篇 |
2004年 | 23939篇 |
2003年 | 22811篇 |
2002年 | 21774篇 |
2001年 | 39126篇 |
2000年 | 39342篇 |
1999年 | 31092篇 |
1998年 | 10711篇 |
1997年 | 11077篇 |
1996年 | 10351篇 |
1995年 | 9971篇 |
1994年 | 9716篇 |
1993年 | 9460篇 |
1992年 | 24996篇 |
1991年 | 24228篇 |
1990年 | 23588篇 |
1989年 | 22935篇 |
1988年 | 21276篇 |
1987年 | 19858篇 |
1986年 | 18389篇 |
1985年 | 18194篇 |
1984年 | 15096篇 |
1983年 | 12608篇 |
1982年 | 9565篇 |
1981年 | 8526篇 |
1980年 | 7978篇 |
1979年 | 13521篇 |
1978年 | 10519篇 |
1977年 | 9462篇 |
1976年 | 8552篇 |
1975年 | 9519篇 |
1974年 | 10160篇 |
1973年 | 10053篇 |
1972年 | 8970篇 |
1971年 | 8186篇 |
1970年 | 6986篇 |
1969年 | 6756篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
A Giustina S Bossoni C Bodini C Ferrari G Pizzocolo T Scalvini M Schettino W B Wehrenberg 《Hormone research》1991,35(3-4):99-103
Subjects with Cushing's disease have diminished growth hormone (GH) response to growth hormone-releasing hormone (GHRH). The aim of our study was to investigate the underlying mechanism of this diminished GH response in these patients using pyridostigmine (PD), an acetylcholinesterase inhibitor, which is reported to increase GH secretion by reducing somatostatin tone. Eight subjects with untreated Cushing's disease (caused by a pituitary adenoma) and 6 control subjects received GHRH 100 micrograms in 1 ml of saline, as intravenous bolus injection 60 min after (1) placebo (2 tablets, p.o.) or (2) PD (120 mg, p.o.). After GHRH plus placebo, the GH peak (mean +/- SEM) was significantly lower in subjects with Cushing's disease (2.4 +/- 0.5 micrograms/l) compared to control subjects (25.1 +/- 1.8 micrograms/l, p less than 0.05). After GHRH plus PD, the GH peak was significantly enhanced both in subjects with Cushing's disease (7.1 +/- 2.3 micrograms/l, p less than 0.05) and in control subjects (42.3 +/- 4.3 micrograms/l, p less than 0.05). In patients with Cushing's disease, the GH response to GHRH plus PD was lower with respect to the GH response to GHRH alone in normal subjects. We conclude that hypercortisolism may cause a decrease in central cholinergic tone which is in turn hypothesized to be responsible of an enhanced somatostatin release from the hypothalamus. However, other metabolic or central nervous system alterations may act synergistically with hypercortisolism in causing GH inhibition in patients with Cushing's disease. 相似文献
52.
Huie M. J.; Casazza G. A.; Horning M. A.; Brooks G. A. 《Journal of applied physiology》1996,80(5):1554-1559
53.
54.
55.
56.
57.
Gerald E. Gaull M.D. 《Neurochemical research》1996,21(10):1267-1268
58.
59.
Chungwen Wei Eugene Storozynsky A. J. McAdam Kun-Yun Yeh Brian R. Tilton Richard A. Willis Richard K. Barth R. John Looney Edith M. Lord J. G. Frelinger 《Cancer immunology, immunotherapy : CII》1996,42(6):362-368
Human prostate-specific antigen (PSA) has a highly restricted tissue distribution. Its expression is essentially limited
to the epithelial cells of the prostate gland. Moreover, it continues to be synthesized by prostate carcinoma cells. This
makes PSA an attractive candidate for use as a target antigen in the immunotherapy of prostate cancer. As a first step in
characterizing the specific immune response to PSA and its potential use as a tumor-rejection antigen, we have incorporated
PSA into a well-established mouse tumor model. Line 1, a mouse lung carcinoma, and P815, a mouse mastocytoma, have been transfected
with the cDNA for human PSA. Immunization with a PSA-expressing tumor cell line demonstrated a memory response to PSA which
protected against subsequent challenge with PSA-expressing, but not wild-type, tumors. Tumor-infiltrating lymphocytes could
be isolated from PSA-expressing tumors grown in naive hosts and were specifically cytotoxic against a syngeneic cell line
that expressed PSA. Immunization with tumor cells resulted in the generation of primary and memory cytotoxic T lymphocytes
(CTL) specific for PSA. The isolation of PSA-specific CTL clones from immunized animals further demonstrated that PSA can
serve as a target antigen for antitumor CTL. The immunogenicity studies carried out in this mouse tumor model provide a rationale
for the design of methods to elicit PSA-specific cell-mediated immunity in humans.
Received: 4 April 1996 / Accepted: 31 May 1996 相似文献
60.